Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edesa Biotech Inc (EDSA)

Edesa Biotech Inc (EDSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,167
  • Shares Outstanding, K 8,334
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,190 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.30
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2750 +12.94%
on 12/24/25
1.6100 -10.56%
on 12/30/25
-0.0400 (-2.70%)
since 12/19/25
3-Month
1.2750 +12.94%
on 12/24/25
2.9500 -51.19%
on 10/22/25
-1.2700 (-46.86%)
since 10/21/25
52-Week
1.2750 +12.94%
on 12/24/25
4.4899 -67.93%
on 02/13/25
-0.3248 (-18.40%)
since 01/21/25

Most Recent Stories

More News
Edesa Biotech Reports Fiscal Year 2025 Results

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 1.4400 (-1.37%)
Interest Rate Decisions Due on Both Sides of Border Next Week

Monday U.S. Featured Earnings Oracle Corp. (NYSE:ORCL) (Q2) EPS for $1.29, compared ...

YEXT : 7.72 (+1.58%)
AVGO : 328.80 (-1.14%)
JOUT : 46.81 (+5.45%)
ORCL : 173.88 (-3.36%)
EDSA : 1.4400 (-1.37%)
TOL : 148.54 (+3.25%)
CIEN : 231.89 (-3.86%)
COST : 982.86 (+1.93%)
FERG : 249.35 (+2.77%)
AZO : 3,671.68 (+2.73%)
ADBE : 294.23 (+1.33%)
SNPS : 521.95 (+2.15%)
Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 1.4400 (-1.37%)
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival...

EDSA : 1.4400 (-1.37%)
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 1.4400 (-1.37%)
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

EDSA : 1.4400 (-1.37%)
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

EDSA : 1.4400 (-1.37%)
Edesa Biotech Announces Chief Financial Officer Transition

EDSA : 1.4400 (-1.37%)
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

EDSA : 1.4400 (-1.37%)
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

EDSA : 1.4400 (-1.37%)

Business Summary

Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.6067
2nd Resistance Point 1.5733
1st Resistance Point 1.5067
Last Price 1.4400
1st Support Level 1.4067
2nd Support Level 1.3733
3rd Support Level 1.3067

See More

52-Week High 4.4899
Fibonacci 61.8% 3.2618
Fibonacci 50% 2.8825
Fibonacci 38.2% 2.5031
Last Price 1.4400
52-Week Low 1.2750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar